76.20
-1.03 (-1.33%)
-1.03 (-1.33%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 777,998 |
|
|||||
News | - | ||||||
Day High | 76.43 | Low High |
|||||
Day Low | 75.30 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
75.30 | 75.30 | 76.43 | 76.25 | 77.23 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
11,138 | 777,998 | $ 76.03 | $ 59,152,370 | - | 55.21 - 81.975 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 17,992 | $ 76.25 | USD |
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 37.34B | 490.09M | 490.09M | $ 8.29B | $ 547.21M | 0.76 | 64.10 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ 0.11 | 0.28% | 05/03/22 | - | - |
Alcon News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 73.97 | 77.90 | 73.65 | 75.84 | 816,617 | 2.23 | 3.01% |
1 Month | 70.76 | 77.90 | 69.67 | 74.18 | 809,020 | 5.44 | 7.69% |
3 Months | 64.83 | 77.90 | 62.72 | 69.59 | 894,314 | 11.37 | 17.54% |
6 Months | 77.28 | 78.22 | 55.21 | 66.10 | 934,327 | -1.08 | -1.4% |
1 Year | 77.47 | 81.975 | 55.21 | 69.64 | 883,600 | -1.27 | -1.64% |
3 Years | 58.98 | 88.78 | 39.37 | 66.45 | 982,477 | 17.22 | 29.2% |
5 Years | 58.245 | 88.78 | 39.37 | 64.37 | 1,040,804 | 17.96 | 30.83% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |